Voxzogo Den europeiske union - norsk - EMA (European Medicines Agency)

voxzogo

biomarin international limited - vosoritide - achondroplasia - legemidler til behandling av bein sykdommer - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Nulibry Den europeiske union - norsk - EMA (European Medicines Agency)

nulibry

tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - andre alimentary tract and metabolism products, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.

Vanflyta Den europeiske union - norsk - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Olmetec 20 mg Norge - norsk - Statens legemiddelverk

olmetec 20 mg

daiichi sankyo europe gmbh - olmesartanmedoksomil - tablett, filmdrasjert - 20 mg

Olmetec 10 mg Norge - norsk - Statens legemiddelverk

olmetec 10 mg

daiichi sankyo europe gmbh - olmesartanmedoksomil - tablett, filmdrasjert - 10 mg

Olmetec 40 mg Norge - norsk - Statens legemiddelverk

olmetec 40 mg

daiichi sankyo europe gmbh - olmesartanmedoksomil - tablett, filmdrasjert - 40 mg

Sevikar 40 mg / 5 mg Norge - norsk - Statens legemiddelverk

sevikar 40 mg / 5 mg

daiichi sankyo europe gmbh - olmesartanmedoksomil / amlodipinbesilat - tablett, filmdrasjert - 40 mg / 5 mg

Sevikar 20 mg / 5 mg Norge - norsk - Statens legemiddelverk

sevikar 20 mg / 5 mg

daiichi sankyo europe gmbh - olmesartanmedoksomil / amlodipinbesilat - tablett, filmdrasjert - 20 mg / 5 mg

Sevikar 40 mg / 10 mg Norge - norsk - Statens legemiddelverk

sevikar 40 mg / 10 mg

daiichi sankyo europe gmbh - olmesartanmedoksomil / amlodipinbesilat - tablett, filmdrasjert - 40 mg / 10 mg

Purevax RCP Den europeiske union - norsk - EMA (European Medicines Agency)

purevax rcp

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katter - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.